The Vision of Translational Research
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
326
On Slideshare
326
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
4
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. The Vision of Translational Research James G. Krueger, MD PhD Co-Director, The Center for Clinical and Translational Science The Rockefeller University New York, New York jgk @rockefeller.edu
  • 2. The Translational Triad
    • Bench to Bedside Research
    • Reverse Translation: Bedside to Bench and Back
    • Mentoring new trainees in all aspects of clinical and translational science, as well as providing needed didactic education
    • We have a small hospital which admits only research patients, so our main focus is Translation I (bench  bedside), rather than Translation II (bedside  community).
  • 3. Bench to Bedside Translation-Our Vision
    • Have ability to support PhD scientists (and their trainees) in accessing human subjects when they want to test a hypothesis in the clinic.
    • Have a center with resources that will permit a scientist to carry a new therapeutic concept into humans with full support for IND application, study conduct under Good Clinical Practice, and housing of research data in FDA-compliant databases with ability for electronic data transfer.
  • 4. Case one: Helping a basic scientist make the clinical leap
    • Provide an infrastructure to help with protocol design, regulatory issues, and informed consent writing
    • Provide access to human subjects through a pool of research coordinators, where a subset of coordinators are nurse practitioners
    • Medical oversight by a Hospitalist and Center Directors
    • Study conduct oversight and monitoring by Clinical Research Support Office staff
  • 5. Case 2: Help a research team go from concept to new drug
    • One example
    A team of basic scientists has discovered that targeting an antigen to dendritic cells as an antibody fusion protein (anti-DEC205+Antigen) is much more effective in inducing T-cell mediated immune responses. They want to use this technology to make a new vaccine for HIV, to be developed and tested in human subjects.
  • 6. Help provided by our Center for Clinical and Translation Science
    • Help with submitting an IND to the FDA--provide advice about regulatory issues including product manufacturing, toxicity testing, stability testing, protocol design, and “pre-IND” discussions with FDA.
    • Help with conducting study under GCP, including design of case report forms, tracking of adverse events, creation of FDA compliant databases, and study monitoring. Access to study coordinators, data mangers, an IT infrastructure, and study monitors is provided within CCTS structure.
  • 7. Deeper scientific resources for translational research
    • Our CCTS will establish a center for human immune monitoring. It will develop techniques and protocols to share with other CTS scientists and the scientific community at large
      • Our center has wide ranging studies in human immunology across many medical disciplines with need for standardized cell-based assays, most of which are likely to use advanced flow cytometric methodologies
      • The development of dendritic cell targeted vaccines also needs assay standardization to quantify T-cell responses to vaccine antigens and presence of specialized leukocyte subsets (e.g., mature dendritic cells).
  • 8. Reverse Translation
    • Have inpatient and outpatient facilities that permit investigators to study human physiology or patients with defined diseases, with a staff attuned to special needs of human subject studies
    • Provide support for access to patients with rare diseases and study support at all levels (design, conduct, oversight and biostatistical analysis of studies), as well as outreach to patient communities with specific diseases
  • 9. A training environment with mentors and graduate courses
    • A center accessible to graduate (PhD) students, medical students, post-docs, medical residents and fellows and allied health professionals, including research nurses to learn about or engage in translational science
    • Formal program for Master’s or PhD in Translational Science
  • 10. Metrics to Measure Outcomes Evaluation of Clinical and Translational Research Improved Health Creation of New Therapeutics, Diagnostics, or Preventive Strategies Identification and Initial Validation of Therapeutic, Diagnostic, or Preventive Targets Scientific Discovery Therapeutics: Phase III Human Studies FDA Approval Clinical Practice Guidelines Diagnostics: FDA Approval Preventive Strategy:Clinical Practice Guidelines Phase I and II Human Studies Patents Issued Licenses Patent Application Invention Disclosures Mechanistic and Genetic Studies in Humans Positive Whole Animal Proof of Concept Studies Improved Understanding of Pathophysiology of Disease or Biologic Processes Inclusion of Concepts in Review Articles and Textbooks Invitation to Speak at Important Meetings Peer Honors Number of Published Papers Quality (Impact Factors) of Journals Peer-Reviewed Grant Support Indicators
  • 11. Priorities and Timelines
    • New Master’s (degree granting) program now open for application; first K-12 supported students begin in 2007
    • New translational graduate course started and open to PhD candidates as of Jan 2007 and will continue/expand going forward
    • Actively building research coordination, GCP infrastructure, IT infrastructure, enhanced statistical support, and regulatory support elements now. Expect operational (interdependent) functionality within 1 year.
  • 12. Priorities and Timelines
    • Immune Monitoring Core actively being assembled and director recruitment in progress
    • New vaccine trials ongoing for some prototypes, but will introduce antibody fusion vaccines and new expression vaccines within 2 years
    • Pilot project grants awarded for first grant year, with out reach to basic scientists; will continue annually
  • 13. Collaboration
    • We want to collaborate with as many CTS centers as possible across all functions of clinical and translational science.
    • Collaboration should be stressed within educational opportunities
    • We have an active plan for development and distribution of unique biostatistical and informatics tools. New tools already developed for biomedical statistics are accessible and can be used via a web interface/grid computing network maintained by our Center.